Email this article Stable angina and heart rate
- Authors: Kirichenko A.A1
-
Affiliations:
- Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
- Issue: Vol 9, No 3 (2018)
- Pages: 25-29
- Section: Articles
- URL: https://journals.rcsi.science/2221-7185/article/view/45944
- DOI: https://doi.org/10.26442/2221-7185_2018.3.25-29
- ID: 45944
Cite item
Full Text
Abstract
The adverse effect of high heart rate (HR) on the course of ischemic heart disease (IHD) is well known. High heart rate can lead to a mismatch between the increased need for myocardium in oxygen and the ability to adequately increase coronary blood flow. A review of the research to study the possibility of reducing heart rate to reduce the number of attacks of angina in patients with IHD, to influence the risk of death and cardiovascular complications. It is shown that the limitation of heart rate for angina pectoris improves the patients' well-being, their tolerance to physical exertion. However, not all classes of drugs affect the prognosis of IHD.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
A. A Kirichenko
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
Email: andrey.apollonovich@yandex.ru
д-р мед. наук, проф., зав каф. терапии №2 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
References
- Морган-мл. Дж.Э., Михаил М.С. Клиническая анестезиология. Книга вторая. Пер. с англ. под ред. А.А.Бунятяна. М.: БИНОМ, 2000.
- Di Francesco D, Camm A. Heart rate lowering by specific and selective if current inhibition with ivabradin. Drugs 2004; 64 (16): 1757-65.
- The b-Blocker Pooling Project Research Group. The beta-blocker pooling project (BBPP): subgroup findings from randomized trial in post infarction patients. Eur Heart J 1988; 9: 8-16.
- Steg P.G, Himbert D. Unmet medical needs and therapeutic opportunities in stable angina. Eur Heart J 2005; 7 (Suppl. H): h7-h15.
- Стрюк Р.И. Клиническое обоснование применения фиксированной комбинации бисопролола с амлодипином при артериальной гипертонии. Consilium Medicum. 2013; 15 (1).
- Borer J, Fox K, Jaillon P, Lerebours G. Ivabradine Investigators Group. Anti-anginal and anti-ischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blinded, multicentered, placebo controlled trial. Circulation 2003; 107: 817-23.
- Tardiff J, Ford I, Tendera M for the INITIATIVE Investigators. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529-36.
- Ruzyllo W, Ford I, Tendera M et al. Antianginal and anti-ischemic effects of If current inhibitor ivabradine compared to amlodipine as monotherapy in patients with chronic stable angina: a 3-month randomized, controlled, double-blind, multicenter trial. Drugs 2007; 67 (3): 393-405.
- Лебедь Е.И., Крючкова О.Н. Использование препарата Кораксан как новое направление в лечении ишемической болезни сердца. Крымский терапевт. журн. 2009; 1: 52-4.
- Tardif J.C, Ponikowski P, Kahan T. ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30 (5): 540-8.
- Fox K, Ford I, Steg P.G et al. Ivabradine for patients with stable coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo controlled trial. Lancet 2008; 372: 807-16.
- Fox K, Ford I, Steg P.G et al; BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372 (9641): 817-21.
- Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376 (9744): 875-85.
- Böhm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013; 102 (1): 11-22.
- Лопатин Ю.М. Оценка антиангинальной эффективности ивабрадина у больных ишемической болезнью сердца, осложненной сердечной недостаточностью. Кардиология. 2015; 5: 5-11.
- Глезер М.Г. От лица участников программы ЛИНКОР. Влияние терапии ивабрадином на качество жизни пациентов со стабильной формой ишемической болезни сердца: результаты программы ЛИНКОР. Кардиология. 2015; 2: 4-9.]
- Карпов Ю.А., Глезер М.Г., Васюк Ю.А. и др. Антиангинальная эффективность и переносимость ивабрадина в терапии пациентов со стабильной стенокардией: результаты исследования КОНТРОЛЬ-2. Кардиоваск. терапия и профилактика. 2011; 10 (8): 83-9.
